From 2013 to 2021, it was estimated that around 11 percent of adults in the United States had been diagnosed with diabetes. In comparison, just over four percent had been diagnosed with myocardial infarction. This statistic depicts the prevalence of select cardiometabolic diseases among adults in the United States from 2013 to 2021.

The cardiometabolic disease market was valued at USD 34.10 Billion in 2024 driven by the rising prevalence of conditions like obesity, diabetes, and cardiovascular diseases as well as risk factors such as sedentary lifestyle and aging population across the 8 major markets. It is expected to grow at a CAGR of 5.40% during the forecast period 2025-2034 and attain a market value of USD 57.70 Billion by 2034.

From 2017 to 2020, it was estimated that around 52 percent of Hispanic males and 37 percent of Hispanic females aged 20 years and older had some cardiovascular disease. This statistic shows the prevalence of cardiovascular diseases among U.S. adults aged 20 years and older in the period from 2017 to 2020, by race/ethnicity and gender.

Spatial distribution with positive and negative influential factors for three cardiometabolic diseases.

Cardiovascular Disease Market Outlook

In 2023, the global cardiovascular disease market size is estimated to be USD 146 billion, and it is projected to reach USD 230 billion by 2032, growing at a CAGR of 5.2%. Growth factors such as the increasing prevalence of cardiovascular diseases, advancements in medical technology, and the rising geriatric population are driving this market towards significant expansion.

The primary growth factor for the cardiovascular disease market is the rising prevalence of cardiovascular conditions worldwide. Factors such as sedentary lifestyles, unhealthy diets, and increasing rates of obesity and diabetes are contributing to the surge in cardiovascular diseases. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. This staggering number underscores the urgent need for efficient diagnostic tools, effective treatments, and preventive measures, all of which fuel market growth.

Technological advancements in the field of medical devices and pharmaceuticals also play a critical role in driving the cardiovascular disease market. Innovative drug formulations and cutting-edge medical devices, such as minimally invasive surgical devices and advanced imaging systems, have significantly improved patient outcomes. For instance, the development of next-generation stents, bioresorbable vascular scaffolds, and wearable heart monitors are some of the key technological innovations that have revolutionized cardiovascular care. These advancements not only enhance the quality of life for patients but also reduce the economic burden on healthcare systems, thereby propelling market growth.

The aging global population is another significant factor contributing to the growth of the cardiovascular disease market. Older adults are more susceptible to cardiovascular conditions such as hypertension, heart failure, and atrial fibrillation. As the global population continues to age, the demand for cardiovascular treatments and diagnostic tools is expected to rise correspondingly. According to the United Nations, the number of people aged 60 and above is projected to double by 2050, reaching approximately 2.1 billion. This demographic shift necessitates increased healthcare investments and innovations in cardiovascular care, further boosting the market.

Regionally, the cardiovascular disease market exhibits varied growth patterns. North America currently dominates the market due to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a significant patient population. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Factors such as rapid urbanization, increasing healthcare awareness, improving healthcare infrastructure, and the rising prevalence of lifestyle-related diseases are driving the market in this region. Countries like China and India are expected to be the major contributors to this growth.

Drug Type Analysis

The cardiovascular disease market can be segmented by drug type into antihypertensive drugs, antithrombotic drugs, lipid-lowering drugs, and others. Antihypertensive drugs are designed to manage high blood pressure, a key risk factor for developing cardiovascular diseases. These drugs, including ACE inhibitors, beta-blockers, and calcium channel blockers, help to reduce the strain on the heart and arteries, thereby lowering the risk of heart attacks and strokes. The growing prevalence of hypertension across the globe is driving demand for these drugs, as patients seek effective management options to mitigate their risk of serious cardiovascular events.

Antithrombotic drugs, which include anticoagulants and antiplatelet agents, are critical in preventing and treating blood clots that can lead to heart attacks and strokes. These drugs work by inhibiting the formation of blood clots or by preventing existing clots from getting larger. The increasing incidence of thrombotic events, particularly among aging populations and those with underlying health conditions like atrial fibrillation, is driving the market for antithrombotic drugs. Innovations in drug formulations and delivery methods are further enhancing their efficacy and safety profiles, making them a cornerstone of cardiovascular disease management.

Lipid-lowering drugs, such as statins, fibrates, and PCSK9 inhibitors, are vital for managing dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. High levels of low-density lipoprotein (

This dataset documents cardiovascular disease (CVD) death rates, relative and absolute excess death rates, and trends. Specifically, this report presents county (or county equivalent) estimates of CVD death rates in 2000-2020, trends during 2010-2019, and relative and absolute excess death rates in 2020 by age group (ages 35–64 years, ages 65 years and older). All estimates were generated using a Bayesian spatiotemporal model and a smoothed over space, time, and 10-year age groups. Rates are age-standardized in 10-year age groups using the 2010 US population. Data source: National Vital Statistics System.

The size of the Cardiometabolic Disease Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of XXX% during the forecast period. Cardiometabolic disease refers to a group of interrelated conditions that increase the risk of developing heart disease, stroke, and type 2 diabetes. These conditions often include obesity, high blood pressure (hypertension), high cholesterol levels, and insulin resistance. The term "cardiometabolic" underscores the connection between the cardiovascular and metabolic systems in the body, reflecting how these health issues are interconnected. Individuals with cardiometabolic risk factors are at a higher likelihood of developing serious complications, including heart attacks, strokes, and metabolic disorders like diabetes. Managing these risk factors through lifestyle changes, such as diet, exercise, and sometimes medication, is crucial for reducing the overall burden of these diseases. The burgeoning prevalence of cardiovascular diseases, diabetes, and obesity, coupled with the growing awareness about preventive healthcare measures, is propelling the demand for effective cardiometabolic disease management solutions. Additionally, technological advancements in diagnostic techniques and treatment modalities are further fueling market expansion.

The cardiovascular disease profiles have been updated by Public Health England (PHE).

The profiles provide an overview of data on cardiovascular and cardiovascular related conditions of heart disease, stroke, diabetes and kidney disease. They are intended to help commissioners and health professionals assess the impact of cardiovascular disease (CVD) on their local population, make decisions about services and improve outcomes for patients.

The cardiovascular disease profiles are one of a range of data and analysis resources produced by PHE’s National Cardiovascular Intelligence Network (NCVIN).

NVCIN has released a range of cardiovascular disease guidance, data and intelligence resources.

This dataset documents rates and trends in local hypertension-related cardiovascular disease (CVD) death rates. Specifically, this report presents county (or county equivalent) estimates of hypertension-related CVD death rates in 2000-2019 and trends during two intervals (2000-2010, 2010-2019) by age group (ages 35–64 years, ages 65 years and older), race/ethnicity (non-Hispanic American Indian/Alaska Native, non-Hispanic Asian/Pacific Islander, non-Hispanic Black, Hispanic, non-Hispanic White), and sex (female, male). The rates and trends were estimated using a Bayesian spatiotemporal model and a smoothed over space, time, and demographic group. Rates are age-standardized in 10-year age groups using the 2010 US population. Data source: National Vital Statistics System.

The global Cardiometabolic Diseases market size was estimated at USD 519.3 billion in 2025 and is projected to reach USD 1,047.7 billion by 2033, exhibiting a CAGR of 8.8% during the forecast period. The rising prevalence of cardiovascular diseases, diabetes, and obesity, along with the increasing geriatric population, are key factors driving market growth. Additionally, advancements in drug therapies and the development of novel treatment options, such as gene therapies and precision medicine, are expected to fuel market expansion. North America is anticipated to account for a significant share of the market due to the high prevalence of cardiometabolic diseases and the presence of advanced healthcare infrastructure. Europe and Asia Pacific are also expected to contribute to market growth, driven by aging populations and increasing healthcare expenditure. Key players in the market include Eli Lilly and Company, Bayer AG, Arrowhead Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., Cardax, Inc., Kowa Company, Ltd., and others.

In 2016, it was estimated that just over half of cardiovascular disease deaths worldwide were related to dietary risks. This statistic shows the percentage of deaths from cardiovascular disease related to selected risk factors worldwide in 2016.

Cardiometabolic Diseases Market Outlook

The global cardiometabolic diseases market size was valued at approximately USD 150 billion in 2023 and is projected to reach nearly USD 230 billion by 2032, growing at a compound annual growth rate (CAGR) of around 4.9% during the forecast period. The growth of this market is primarily driven by increasing prevalence of lifestyle-related diseases, advancements in medical technology, and rising awareness about early diagnosis and management of these conditions.

The surge in sedentary lifestyles, poor dietary habits, and increasing levels of stress have significantly contributed to the rise in cardiometabolic diseases globally. These conditions, including diabetes, hypertension, dyslipidemia, obesity, and cardiovascular diseases, are becoming increasingly common. The aging population is also a major factor driving the market growth. As the elderly are more susceptible to these diseases, the demand for diagnostic and treatment options is expected to rise. Additionally, the growing awareness about the importance of early detection and management of cardiometabolic diseases is propelling the market forward.

Technological advancements in medical devices and treatment options have dramatically improved the management of cardiometabolic diseases. Innovations such as continuous glucose monitoring systems, minimally invasive surgical procedures, and new pharmacological therapies have enhanced the efficacy and convenience of treatments. These technological developments are expected to further fuel market growth, as they offer improved outcomes for patients and reduce the overall burden of these diseases. Moreover, the integration of artificial intelligence and machine learning in diagnostic tools is aiding in the early detection of cardiometabolic conditions, thereby improving patient prognosis.

Government initiatives and healthcare policies aimed at controlling the prevalence of cardiometabolic diseases are also playing a significant role in market growth. Many countries are implementing national health programs focused on screening, prevention, and management of these conditions. These initiatives not only enhance public awareness but also improve access to healthcare services, particularly in low and middle-income countries. Furthermore, the increasing investment in healthcare infrastructure and research and development activities by both public and private sectors is anticipated to boost the market.

Cardiomyopathy Medication plays a crucial role in the management of cardiometabolic diseases, particularly in conditions where the heart muscle is affected. These medications are designed to improve heart function and prevent further deterioration by managing symptoms and reducing the risk of complications. The development of novel cardiomyopathy drugs has been a focus for many pharmaceutical companies, aiming to enhance patient outcomes and quality of life. These medications often work by targeting specific pathways involved in heart muscle function, offering tailored treatment options for patients with different types of cardiomyopathy. With ongoing research and clinical trials, the landscape of cardiomyopathy treatment is continually evolving, promising more effective and personalized therapeutic options in the future.

Regionally, North America dominates the cardiometabolic diseases market, owing to high prevalence rates, advanced healthcare infrastructure, and substantial healthcare expenditure. Asia Pacific is expected to witness the highest growth rate during the forecast period, driven by increasing incidence of these diseases, improving healthcare facilities, and rising health awareness among the population. Europe also holds a significant share in the market, supported by robust healthcare systems and extensive research activities. The Middle East & Africa and Latin America are emerging markets with considerable growth potential, primarily due to improving healthcare access and rising disease awareness.

Diabetes Analysis

Diabetes is a major segment within the cardiometabolic diseases market, characterized by high levels of blood sugar caused by either insufficient insulin production or insulin resistance. The increasing prevalence of diabetes globally is a significant driver for this segment. Factors such as sedentary lifestyle, unhealthy eating habits, and genetic predisposition contribute to the rising incidence of diabetes. Moreover, the growing aging population, which is more susceptible t

Update 2 March 2023: Following the merger of NHS Digital and NHS England on 1st February 2023 we are reviewing the future presentation of the NHS Outcomes Framework indicators. As part of this review, the annual publication which was due to be released in March 2023 has been delayed. Further announcements about this dataset will be made on this page in due course. Directly standardised mortality rate from cardiovascular disease for people aged under 75, per 100,000 population. To ensure that the NHS is held to account for doing all that it can to prevent deaths from cardiovascular disease in people under 75. Some different patterns have been observed in the 2020 mortality data which are likely to have been impacted by the coronavirus (COVID-19) pandemic. Statistics from this period should also be interpreted with care. Legacy unique identifier: P01730

BackgroundAmerican Indians and Alaska Native (AI/AN) populations experience significant health disparities compared to non-Hispanic white populations. Cardiovascular disease and related risk factors are increasingly recognized as growing indicators of global health disparities. However, comparative reports on disparities among this constellation of diseases for AI/AN populations have not been systematically reviewed.ObjectivesWe performed a literature review on the prevalence of diabetes, metabolic syndrome, dyslipidemia, obesity, hypertension, and cardiovascular disease; and associated morbidity and mortality among AI/AN.Data sourcesA total of 203 articles were reviewed, of which 31 met study criteria for inclusion. Searches were performed on PUBMED, MEDLINE, the CDC MMWR, and the Indian Health Services.Study eligibility criteriaPublished literature that were published within the last fifteen years and provided direct comparisons between AI/AN to non-AI/AN populations were included.Study appraisal and synthesis methodsWe abstracted data on study design, data source, AI/AN population, comparison group, and. outcome measures. A descriptive synthesis of primary findings is included.ResultsRates of obesity, diabetes, cardiovascular disease, and metabolic syndrome are clearly higher for AI/AN populations. Hypertension and hyperlipidemia differences are more equivocal. Our analysis also revealed that there are likely regional and gender differences in the degree of disparities observed.LimitationsStudies using BRFSS telephone surveys administered in English may underestimate disparities. Many AI/AN do not have telephones and/or speak English. Regional variability makes national surveys difficult to interpret. Finally, studies using self-reported data may not be accurate.Conclusions and implications of key findingsProfound health disparities in cardiovascular diseases and associated risk factors for AI/AN populations persist, perhaps due to low socioeconomic status and access to quality healthcare. Successful programs will address social determinants and increase healthcare access. Community-based outreach to bring health services to the most vulnerable may also be very helpful in this effort.Systematic review registration numberN/A

The Cardiometabolic Disease Market offers a range of products, including:Pharmaceuticals: Drugs used to manage blood pressure, cholesterol, and blood sugar levels, such as ACE inhibitors, statins, and metformin.Medical Devices: Devices used for diagnosis and treatment, such as electrocardiograms (ECGs), implantable cardioverter-defibrillators (ICDs), and pacemakers.Services: Diagnostic tests, imaging services, and cardiac rehabilitation programs. Recent developments include: October 2022 To encourage medical professionals (HCPs) to prioritize an integrated strategy to care for cardio-renal-metabolic (C-R-M) conditions given the cardiovascular, renal (kidney), and metabolic systems' close interconnection and shared disease-related pathways, Eli Lilly and Company and Boehringer Ingelheim launched CRMSynced., June 2021 The ACC and GE Healthcare worked together to create a roadmap for AI and digital cardiology technologies and novel approaches for better health outcomes with the help of and involvement in the ACC's Applied Health Innovation Consortium (AHIC)., August 2021 Bayer announced detailed data from the Phase III FIGARO-DKD research demonstrating that compared to placebo, the investigational medicine finerenone lowered the risk of cardiovascular (CV) disease in a broad population of patients with stages 1-4 of chronic kidney disease (CKD) and type 2 diabetes (T2D). Notable trends are: The growing prevalence of cardiometabolic disorders boosts the market growth.

According to the findings of a survey by IPSOS, every country in the study underestimated the number of people who die each year from cardiovascular diseases such as heart disease. Those in South Africa and Hong Kong had the most accurate guesses, with the average guess being 9 percent below the actual percentage. This statistic shows the actual vs public estimates for number of deaths per 100 which occur as a result of cardiovascular disease worldwide as of 2019.

Global Cardiometabolic Diseases market size is expected to reach $137.81 billion by 2029 at 4.5%, rising obesity rates fuel growth in cardiometabolic disease market

In 2020, the mortality rate due to cardiovascular disease (CVD) was highest in Bulgaria with approximately 1,077 deaths per 100,000 population. In Ukraine, CVD caused around 930 deaths per 100,000. On the other hand, Luxembourg had the lowest mortality rate at fewer than 160 deaths per 100,000.

Cardiovascular Disease Prevalence in Travis County (2014-2018)

Assessing Risk Factors in an Urban Community

By City of Austin [source]

About this dataset

This dataset provides invaluable insight into the prevalence of cardiovascular disease in Travis County, Texas between 2014 and 2018. By utilizing data from the Behavioral Risk Factor Surveillance System (BRFSS), this dataset offers a comprehensive look at the health of the adult population in Travis County. Are your heart health concerns growing or declining? This dataset has the answer. Through its detailed analysis, you can quickly identify any changes in cardiovascular disease over time as well as understand how disability and other factors such as age may be connected to heart-related diagnosis rates. Investigate how diabetes, lifestyle habits and other factors are affecting residents of Travis County with this insightful strategic measure!

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset provides valuable insight into the prevalence of cardiovascular disease among adults in Travis County from 2014 to 2018. The data includes a Date_Time variable, which is the date and time of the survey, as well as a Year variable and Percent variable detailing prevalence within that year. This data can be used for further research into cardiovascular health outcomes in Travis County over time.

The first step in using this dataset is understanding its contents. This data contains information on each year’s percent of residents with cardiovascular disease and was collected during annual surveys by Behavioral Risk Factor Surveillance System (BRFSS). With this information, users can compare yearly changes in cardiovascular health across different cohorts. They can also use it to identify particular areas with higher or lower prevalence of cardiovascular disease throughout Travis County.

Now that you understand what’s included and what it describes, you can start exploring deeper insights within your analysis. Try examining demographic factors such as age group or sex to uncover potential trends underlying the increase or decrease in overall percentage over time . Additionally, look for other data sources relevant to your research topic and explore how prevalence differs across different factors within Travis County like specific counties or cities within it or types of geographies like rural versus urban settings . By overlaying additional datasets such as these , you will learn more about any correlations between them and this BRFSS-surveyed measure overtime .

Finally remember that any findings related to this dataset should always be interpreted carefully given their scale relative to our broader population . Yet by digging deep into the changes taking place , we are able to answer important questions about howCV risk factors might vary from county-to-county across Texas while also providing insight on where public health funding should be directed towards next !

Research Ideas

• Evaluating the correlation between cardiovascular disease prevalence and socio-economic factors such as income, education, and occupation in Travis County over time.
• Building an interactive data visualization tool to help healthcare practitioners easily understand the current trends in cardiovascular disease prevalence for adults in Travis County.
• Developing a predictive model to forecast the future prevalence of cardiovascular disease for adults in Travis County over time given relevant socio-economic factors

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

See the dataset description for more information.

Columns

File: strategic-measure-percentage-of-residents-with-cardiovascular-disease-1.csv | Column name | Description | |:--------------|:---------------------------------------------------------------------------| | Date_Time | Date and time of the survey. (DateTime) | | Year | Year of the survey. (Integer) | | Percent | Percentage of adults in Travis County with cardiovascular disease. (Float) |

Acknowledgements

If you use this dataset in your research, please credit the original authors. If you use this dataset in your research, please credit City of Austin.